GAROFALO ELIZABETH A. 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 11, 2024
Insider Transaction Report
Form 4
GAROFALO ELIZABETH A.
Director
Transactions
- Exercise/Conversion
Common Shares
2024-03-08$18.56/sh+3,500$64,960→ 3,500 total - Tax Payment
Common Shares
2024-03-08$46.16/sh−1,408$64,993→ 2,092 total - Sale
Common Shares
2024-03-08$45.69/sh−2,092$95,583→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-08−3,500→ 16,500 totalExercise: $18.56Exp: 2031-06-02→ Common Shares (20,000 underlying)
Footnotes (2)
- [F1]Represents the closing price of the Company's common shares on March 7, 2024 for purposes of net settlement calculations.
- [F2]One-third of the total shares subject to the Option vested on the one year anniversary of the grant date, one-third of the total shares subject to the Option vested on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.